C4 Therapeutics, Inc. SEC Filings

C4 Therapeutics (CCCC) launched a primary offering of 21,895,000 shares of common stock and pre-funded warrants to purchase up to 28,713,500 shares, each sold with accompanying Class A and Class B warrants to purchase an aggregate 50,608,500 shares under each class. The combined public offering prices were $2.47 per share unit and $2.4699 per pre-funded warrant unit, for gross proceeds of $125,000,123.65 and underwriting discounts of $7,500,179.70, resulting in proceeds to the company of $117,499,943.95 before expenses.

The Class A and Class B warrants have $2.22 exercise prices (or $2.2199 per pre-funded warrant). Class A warrants are exercisable after issuance and expire on the earlier of 30 days following the public release of nine‑month median follow-up data from any expansion cohort in the planned Phase 1b cemsidomide/elranatamab study or five years; Class B warrants expire five years after issuance and may be mandatorily exercised on or after six months if the stock closes above $6.66 for ten consecutive trading days. Common shares are listed on Nasdaq as CCCC; the warrants and pre-funded warrants will not be listed. Shares outstanding were 71,007,083 as of June 30, 2025.

The company expects to use net proceeds, together with $223.0 million of cash, cash equivalents and marketable securities as of June 30, 2025, to fund ongoing and planned cemsidomide clinical trials, other R&D, and for working capital and general corporate purposes.

C4 Therapeutics announced an underwritten equity offering consisting of 21,895,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 28,713,500 shares. Each share or pre-funded warrant was sold together with accompanying Class A and Class B warrants, at a combined price of $2.47 per share package and $2.4699 per pre-funded package. The company expects approximately $117.0 million in net proceeds, extending its cash runway to the end of 2028. If all warrants are cash exercised in full, aggregate net proceeds are expected to be $341.7 million. Closing is expected on October 17, 2025, subject to customary conditions.

The pre-funded warrants have a $0.0001 exercise price and do not expire. Class A and Class B warrants each have an initial exercise price of $2.22 per share and are exercisable immediately. Class A warrants expire on the earlier of 30 days after public release of nine-month median follow-up data from any expansion cohort in the planned Phase 1b study of cemsidomide with elranatamab or the fifth anniversary; Class B warrants expire on the fifth anniversary and may be mandatorily exercised after six months if the stock closes above $6.66 for ten consecutive trading days. Warrant exercises are subject to a Beneficial Ownership Limitation of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ notice.

C4 Therapeutics form 4 disclosure: A company director, Kenneth Carl Anderson, acquired 5,349 shares of C4 Therapeutics common stock as compensation in lieu of cash, at a price equal to the stock's closing market price of $2.15 on the transaction date. After the issuance, the reporting person directly beneficially owns 140,574 shares and reports additional indirect holdings through trusts and a spouse totaling multiple separate share blocks: 47,316 (spouse), 61,265 (2016 GRAT), 61,265 (spouse's 2016 GRAT), 16,939 (2015 irrevocable trust), and 16,939 (spouse's 2015 irrevocable trust). The filing states these trust-held shares are disclaimed except to the extent of pecuniary interest. The acquisition was made under the issuer's Non-Employee Director Compensation Policy, reflecting an election to take equity instead of cash for board service.

Donna Grogan, a non-employee director of C4 Therapeutics, Inc. (CCCC), received 6,740 shares of common stock on 10/01/2025 by electing to take equity in lieu of cash under the company’s Non-Employee Director Compensation Policy. The shares were recorded at a per-share price of $2.15, equal to the closing market price on the transaction date. After the grant, the reporting person beneficially owned 58,629 shares, held directly. The Form 4 discloses the transaction code and confirms the shares were issued as director compensation.

C4 Therapeutics, Inc. announced on October 1, 2025 that it entered a clinical trial collaboration and supply agreement with Pfizer. Under the agreement, Pfizer will supply elranatamab (ELREXFIO®), a BCMAxCD3 bispecific antibody, at no cost for C4's upcoming Phase 1b trial testing the safety and tolerability of cemsidomide plus dexamethasone in combination with elranatamab for patients receiving second-line or later therapy for multiple myeloma. C4 will sponsor and run the trial while Pfizer will receive access to trial data. The company furnished a press release as Exhibit 99.1 to the current report.

C4 Therapeutics, Inc. (CCCC) reported that it issued a press release and presented clinical data from its Phase 1 trial of cemsidomide plus dexamethasone for relapsed/refractory multiple myeloma at the International Myeloma Society (IMS) Meeting in an oral presentation on September 20, 2025. The company furnished the press release as Exhibit 99.1 and posted the presentation slides on its investor relations site, filing those slides as Exhibit 99.2 to this Current Report on Form 8-K. The filing states these materials are "furnished" (not "filed") and does not include financial results or detailed trial outcomes within the Form text. The company also notes the furnishing does not constitute an admission as to materiality.

C4 Therapeutics insider filing: The reporting person, Kendra Adams (CFO), acquired 6,250 shares of common stock on 09/18/2025 upon vesting of previously granted restricted stock units (RSUs). The shares were issued at no cash price upon vesting and increased her beneficial holdings to 165,117 shares. In connection with the vesting, the issuer withheld 2,775 shares to satisfy tax withholding obligations, which reduced the net shares delivered and left 162,342 shares listed after the withholding entry on the Form 4.

C4 Therapeutics (NASDAQ: CCCC) Q2 2025 10-Q highlights

• Revenue: $6.5 m from collaborations, down 46 % YoY (Q2 24: $12.0 m) as Biogen–related income rolled off.
• Expenses: R&D $26.2 m (+10 % YoY); G&A $8.8 m (-10 % YoY). Total op-ex $35.0 m (+4 %).
• Losses: Operating loss widened to $28.5 m; net loss $26.0 m (-$0.37 pps) versus $17.7 m (-$0.26 pps) a year ago. 1H 25 net loss $52.3 m.
• Cash runway: Cash, cash equivalents & marketable securities were $223 m at 6-30-25 (vs. $267 m at 12-31-24); management projects ≥12-month runway.
• Balance sheet: Deferred revenue $43.8 m, reflecting future work under Roche, MKDG, Merck and Betta deals; no debt.
• Collaboration momentum: Earned $1 m discovery milestone (MKDG) and two $2 m lead-series milestones (Roche). Q2 revenue mix: MKDG 53 %, Roche 30 %, Merck 16 %, Betta 1 %.
• Share count: 71.2 m outstanding (7-29-25) after equity comp and ESPP; authorized shares doubled to 300 m.
• Guidance & risk: Company remains clinical-stage with no product sales; relies on external funding and partner milestones; accumulated deficit $686 m.

The filing affirms strategic focus on protein-degrader oncology programs (e.g., CFT8919, DACs) while controlling G&A. Near-term catalysts hinge on progress within partnered pipelines and internal Phase 1 assets.